Effect of depot medroxyprogesterone acetate and testosterone oenanthate on serum lipoproteins in man.
Ten normal men were given three monthly intramuscular injections of 200mg of depot medroxyprogesterone acetate (DMPA) and 250mg of testosterone oenanthate (TE) as part of a male contraceptive trial. During the three months of treatment, serum high density lipoprotein cholesterol (HDL-C) and the HDL-C:LDL-C (low density lipoprotein cholesterol) ratio were significantly depressed compared to baseline. Although the long-term effect of this alteration in lipoprotein cholesterol metabolism in normolipidaemic men is currently uncertain, these results suggest that the potential cardiovascular risks of progestagen-containing regimens for male contraception will have to be seriously considered.
Wallace
E M
EM
MRC Reproductive Biology Unit, Centre for Reproductive Biology, Edinburgh, Scotland.
Wu
F C
FC
D000328:Adult; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003272:Contraceptive Agents, Male; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008525:Medroxyprogesterone / Q000031:analogs & derivatives*; D017258:Medroxyprogesterone Acetate; D013739:Testosterone / Q000031:analogs & derivatives*
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D003272:Contraceptive Agents, Male; D008074:Lipoproteins; D013739:Testosterone; C004648:testosterone enanthate; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone